# Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients

> **NCT07314294** · PHASE2 · RECRUITING · sponsor: **Shanghai EpimAb Biotherapeutics Co., Ltd.** · enrollment: 54 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** EMB-01 1600 mg administered once weekly throughout the study
- **DRUG:** EMB-01 1600 mg once weekly for 6 weeks, then every 2 weeks thereafter

## Key facts

- **NCT ID:** NCT07314294
- **Lead sponsor:** Shanghai EpimAb Biotherapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-18
- **Primary completion:** 2027-12-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07314294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07314294, "Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07314294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*